/Lists

Biotech Late Stage Investors & VC Firms

360 firms in this list, with a median first check of $1M. 82 of them lead rounds. Generated from verified public data and updated continuously.

aMoon
Ra'ananaSeed–Late Stage
34 people
Berkeley Frontier
BerkeleyPre-Seed–Late Stage
40 people
DAYLI Partners
SeoulSeed–Late Stage
13 people
Cross Creek Advisors
Salt Lake CitySeries B–Late Stage
21 people
B4 Capital
Seed–Late Stage$10M – $50M
2 people
Odyssey Investment Partners
New YorkGrowth–Late Stage$100M – $300M
25 people
Asahi Kasei Corporate Venture Capital
Menlo ParkPre-Seed–Late Stage$200K – $5M
25 people
Avoro Capital Advisors
New YorkSeries A–Late Stage
22 people
BioGeneration Ventures
NaardenPre-Seed–Late Stage
26 people
ARCHIMED Japan
LyonGrowth–Late Stage$10.8M – $1.1B
22 people
Gilde Healthcare
UtrechtSeed–Late Stage$1.1M – $55M
26 people
EcoR1 Capital
San FranciscoSeed–Late Stage
17 people
Agent Capital
WalthamSeed–Late Stage
24 people
Blue Ocean Capital Group
ShenzhenLate Stage
31 people
Peregrine Ventures
Or YehudaSeed–Growth$500K – $3M
16 people
Impact Fund Denmark
CopenhagenSeed–Late Stage$2.2M – $70.2M
36 people
Claret Capital Partners
LondonSeries A–Late Stage
27 people
Bootstrap Europe
LondonGrowth–Late Stage
23 people
Corewell Health Ventures
Grand RapidsSeries B–Late Stage
5 people
EUREKA! Venture
MilanSeed–Late Stage
23 people
Bay City Capital
San RafaelSeed–Late Stage$5M – $10M
8 people
IDG Capital
Hong KongPre-Seed–Late Stage$1M – $100M
8 people
Arkin Capital
HerzliyaSeed–Late Stage
28 people
Sampac Tech Fund
Palo AltoSeed–Late Stage
31 people

Related lists

Data sourced from public filings and firms' own websites — see our methodology.